Douglas Gladstone is an Oncology physician. OpenAlex indexes 194 publications with 5,375 citations (h-index 39); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1650 Orleans St
Crb I , Suite 287 - Oncology
Baltimore, MD 212870013
Telephone
443-287-6471Registry record last updated 16 Apr 2014.
Clinical trials
- Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Phase II High-Dose Cyclophosphamide for Multiple Sclerosis
Sponsor: Stony Brook University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20253 payments
- Adaptive Biotechnologies CorporationProgram year202514 payments
- BeOne Medicines USA, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
44%Kinase inhibitor31.1%Calquence73%Brukinsa27%Part D<11 patientsBCL-2 Inhibitor12.9%Venclexta100%Part D<11 patientsAnti-infectives
19.9%Short-acting sulfonamides14.9%Sulfamethoxazole-Trimethoprim100%Part D≥12 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor5%Valacyclovir100%Part D<11 patientsNervous system
18.7%Other antidepressants10%Mirtazapine100%Part D<11 patientsSNRI8.7%Duloxetine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”